bezlotoxumab + Vancomycin Oral
ApprovedCompleted 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Clostridium Difficile Infection Recurrence
Conditions
Clostridium Difficile Infection Recurrence
Trial Timeline
Jun 25, 2019 → Nov 18, 2021
NCT ID
NCT03880539About bezlotoxumab + Vancomycin Oral
bezlotoxumab + Vancomycin Oral is a approved stage product being developed by Merck for Clostridium Difficile Infection Recurrence. The current trial status is completed. This product is registered under clinical trial identifier NCT03880539. Target conditions include Clostridium Difficile Infection Recurrence.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03880539 | Approved | Completed |
Competing Products
20 competing products in Clostridium Difficile Infection Recurrence